CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 Trial.
- Citation:
- Meeting Instance:
- ESMO 2016
- Year:
- 2016
- Type:
- Abstract
- Sub type:
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- Yes
- Parents:
- None
- Children:
- 2604
- Pharmas:
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- Toni K. Choueiri Susan Halabi Ben L. Sanford Olwen Hahn M. Dror Michaelson Meghara Walsh Thomas Olencki Joel Picus Eric J. Small Daniel George Shaker Dahkil Michael J. Morris
- Networks:
- CA136, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NC010, LAPS-NY016, LAPS-OH007
- Study
- Alliance-A031203
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: